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INTRODUCTION 
The research described here is a continuation of an ongoing project whose aim is the 
synthesis and characterization of derivatives of (±)-threo -methylphenidate (TMP; Ritalin©) with 
potential in the treatment of cocaine (COC) abuse 1, 2, 3, 4, 5, 6, 7 . The reinforcing and stimulant 
effects of COC are thought to be due, at least in part, to the drug’s ability to block dopamine 
(DA) re-uptake by binding to a stimulant binding site on the DA transporter located at the DA 
nerve terminal 8, 9.  TMP also binds to this site, as identified using the radioligand 3H-WIN 35, 
428 (WIN) 1. The premise of this work is that modification of the TMP molecule may result in 
one of two possible modes of pharmacotherapies for use in the treatment of COC abuse: (1) a 
classic cocaine antagonist which will block the binding of cocaine to the DA transporter, but 
have no intrinsic effect on the uptake of DA, or (2) a long-acting cocaine agonist/partial agonist 
which can be administered as a cocaine substitute with less reinforcing properties, analogous 
to the use of methadone for the treatment of heroin addiction. 
 
Although COC and TMP are similar in their ability to block DA transport, they differ markedly in 
their activity at the serotonin (5-HT) transporter 5. TMP has virtually no activity against 5-HT 
uptake, while COC is a potent 5-HT uptake blocker. Displacement of 3H-citalapram (CIT) 
binding is commonly used to measure activity at the 5-HT transporter. Measurement of the 
activity of these TMP derivatives against CIT binding was performed in order to determine 
whether the pharmacological profiles of these modified compounds more closely resemble 
TMP or COC. 
 
Previous work from our laboratories has focused primarily on the effect of substituents added 
to the phenyl ring of TMP 1 , removal of its phenyl ring 3 , N-substitution 2, 10, alteration of the 
size of the heterocyclic ring 4, restricted rotation analogues  6, and/or modification of the ester 
function 5 ,7.  For the convenience of the reader, we have summarized much of our previous 
WIN binding data in Table A of the Appendix, which appears at the end of this paper. Please 
note that all of the compound numbers in Table A are preceded by an “M” prefix to distinguish 
them from the numbers assigned to the compounds described in this report, which do not have 
an alphabetical prefix.  Other laboratories have explored the effect of replacement of the ester 
group with alkyl moieties 11.This work continues the examination of the effect of modification or 
replacement of the ester group on the TMP molecule with other functional groups, as well as 
substitution at the piperidine N and addition of 3,4 dichloro groups to the phenyl ring. The 
eleven compounds described here were quantified by their potency against WIN and CIT 
binding, as well as their effect on DA uptake. 
 
RESULTS AND DISCUSSION 
 
PHARMACOLOGY 
WIN BINDING 
 
  
The WIN binding data (and all other biological data) for the eleven TMP derivatives are shown 
in Table 1, arranged in order of decreasing potency at the WIN binding site. Potency is 
expressed as IC50 (the concentration of a test compound that inhibits control radioligand 
binding or uptake by 50%). Data for TMP (M39) and COC are included for comparison 
purposes. 
   
Table 1. Structures and Biological Testing of (±)-Threo-methylphenidate Analogs 
 
 
 
 
 
 
 
 
a
 nH = the Hill coefficient of binding 
 
Three of these compounds, (1, 2 and 6), have ether groups in place of the ester function of 
TMP. Ethyl ether 6 is approximately equipotent to TMP (see Table 2 for comparison of 
potencies) and is only modified at the ester position. This confirms earlier work that showed 
that the corresponding methyl ether of TMP (M68, IC50=97.1 nM) 
7 was little different than 
TMP. Compounds 1 and 2 have three times greater affinity for the WIN binding site than TMP 
itself, but are both substituted at the piperidine nitrogen, whereas TMP is a secondary amine. 
In addition, 2 is a 3,4-dichloro analog. Direct comparisons are difficult. 
 
There are three compounds, 7, 3, and 4, with a double bond at position Y instead of the ester 
group. Respectively, the double bonds are unsubstituted, or have a methyl ester or phenyl 
group at the second carbon. These compounds are only modified at the ester position. 
Ethylene analog 7 is essentially as active as TMP, confirming earlier work that nonpolar groups 
at this position do not lower potency 11.  Interestingly, 3 and 4, with an ester or phenyl group, 
respectively, are twice as potent as TMP at the WIN binding site. When the double bonds of 3 
and 4 are saturated to yield 8 and 9 there is a 4-fold loss in affinity (2-fold less potent than 
TMP). Thus, the nonpolar methyl ester or phenyl groups help affinity when trans attached to 
the double bond, but lower affinity in the less constrained saturated compounds. Obviously, 
there are some complicated steric considerations at this position. 
Cpd 
No. X Y Z 
WIN CIT DA 
IC50 (nM) nH 
a 
IC50 (nM) nH 
a 
IC50 (nM) 
COC    160 ± 15 1.03 ± 0.01 401 ± 27 1.27 ± 0.01 404 ± 26 
TMP H CO2CH3 H 84.3 ± 6.3 0.92 ± 0.07 >>10,000 -- 230 ± 16 
1 H CH2OCH2CH3 benzyl 27.0 ± 2.0 1.58 ± 0.01 <<10,000 -- 54.5 ± 1.5 
2 3,4-diCl CH2OCH3 CH3 28.0 ± 2.0 1.16 ± 0.04 468 ± 120 1.29 ± 0.01 66.5 ± 1.5 
3 H t-CH=CHCO2CH3 H 40.0 ± 2.0 0.94 ± 0.07 >10,000 - 120 ± 6.5  
4 H t-CH=CHPh H 40.2 ± 2.2 0.92 ± 0.04 6232 ± 86 1.00 ± 0.19 79.5 ± 7.5 
5 3,4-diCl CH2OH CH3 64.2 ± 1.2 1.01 ± 0.00 382 ± 12 1.27 ± 0.10 220 ± 21 
6 H CH2OCH2CH3 H 106 ± 1.0 0.98 ± 0.02 3,740 (1) 0.76 (1) 221 ± 21 
7 H CH=CH2 H 109 ± 12 0.95 ± 0.03 >10,000 -- 242 ± 15 
8 H CH2CH2CO2CH3 H 168 ± 11 0.88 ± 0.01 >10,000 -- 374 ± 14 
9 H CH2CH2Ph H 193 ± 10 1.06 ± 0.06 3,160 ± 390 1.25 ± 0.05 340 ± 20 
10 3,4-diCl =CH2 CH3 645 ± 42 1.15 ± 0.05 411 (1) 1.21 3,350 ± 340 
11 H CH2OH CH3 7,030 ± 270 1.21 ± 0.16 >10,000 -- 12,700 ± 2,600 
Y
N
Z
X
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CO2CH3
O
O
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H
H
  
 
Two compounds, 5 and 11, have primary alcohol groups in place of the ester function of TMP. 
Both are N-substituted with methyl groups and in addition 5 is a 3,4-dichloro analog. Previous 
work showed that the conversion of the ester to alcohol 7 (M30) o r N-methylation 5 (M77) of 
TMP lowered affinity by 5 to 6-fold. If these effects are additive, then 11 might be expected to 
be 25 to 30-fold less active than TMP, whereas it is actually 83-fold less active, considerably 
more than additive. However, the effect of N-methyl substitution can vary as can be seen if we 
compare 2 to the previously reported  compound (M62) without the N-methyl (16-fold loss) 7. 
Interestingly, 5 is about as active as TMP. This shows the large effect (110-fold increase 
comparing 5 and 11) on affinity that 3,4-dichloro substitution can have. This “3,4-dichloro 
substitution effect” has been studied in detail 6, and the results in this paper are perfectly 
consistent.  
 
In contrast to N-methyl substitution, N-benzyl substitution enhanced affinity for the WIN binding 
site (N-benzyl ethyl ether 1 is 4-fold more potent than 6, the ethyl ether with no substitution on 
the N).  This is consistent with previously published data 5, 7, 10  showing that N-benzyl 
substitution of TMP derivatives without modification of the phenyl ring of the parent compound 
enhances affinity for the WIN binding site anywhere from 1.6 (for TMP itself [M29]) to 19-fold 
(for M66, the primary alcohol analog of TMP).  See Table A, Appendix. 
 
The most unique compound in this study is 10 which has a sp2 hybridized carbon directly 
attached to position Y. It is formally not a threo compound as there is only one asymmetric 
carbon. Obviously the geometry in this area of the molecule would be very different than TMP. 
The best comparison would be to 3,4-dichloro N-methyl TMP, but this compound has not been 
synthesized. Closely related is 3-chloro N-methyl TMP (M41), which shows an IC50 of 160 nM 
5. (3,4-dichloro TMP M52 is equipotent to 3-chloro TMP M50). Using M41 as the model 
compound, 10 is only 4-fold less potent than the corresponding threo methyl ester.  
 
The data reported here allow further examination of another characteristic feature sometimes 
observed with 3,4-dichloro derivatives of the phenyl ring: a monotonic increase in the Hill 
coefficient (nH) of WIN binding from one (denoting no positive cooperativity) to two (suggesting 
that there may be two interacting WIN binding sites).   To aid in this discussion, nH values for 
the compounds to be compared are reported in Table 2. The complete selection from which 
the compounds of interest have been culled is shown in Table A, Appendix, along with their nH 
values and IC50’s against WIN binding.  This doubling of the nH was first noted with the 3,4-
dichloro TMP itself 1 (M52 in Table 2).  It does not happen in all compounds with 3,4 dichloro 
substitutions of the phenyl ring, however, indicating that several factors may contribute to the 
ability of these derivatives to bind in the proper orientation to induce positive cooperativity. 
None of the newly synthesized dichloro compounds reported in this paper exhibit this feature 
(2, 5 and 10), but comparison of their Hill coefficients with available data from related 
compounds yields some emerging patterns that may merit further investigation. Examination of 
the accumulated data shows that the increase of the Hill coefficient to 2 occurs upon 
chlorination of the TMP molecule when the ester is retained and no N-substitution is 
introduced, as mentioned above. It does not occur with dichlorinated derivatives having an 
unsubstituted piperidine amine, but in which the ester group is replaced by an ether, alcohol, or 
amide (Table 2, M62, M61, and M72, respectively). The Hill coefficient also remains at unity 
when the ester group is replaced in the dichlorinated derivative by one of the above functional 
groups and a methyl group is added to the N (Table 2: 2, 5 and 10). Strikingly, however, if the 
N-Me group is replaced by an N-benzyl group in these dihalogenated derivatives, the Hill 
  
coefficient rises to two whether the ester function is present (Table 2: M69) , or has been 
replaced by an ether (M71) or an alcohol (M70) . N-benzyl substitution in the absence of the 
phenyl ring chlorine substitutions is not sufficient by itself to induce positive cooperativity, as 
evidenced by M29, M67, and M66, which have Hill coefficients of one. 
 
Table 2.  Effect of Functional Groups on Hill Coefficient of WIN Binding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a nH  values expressed as mean ± SEM 
 
Perusal of Table A, Appendix, shows that some compounds that are not dichlorinated also 
exhibit nH’s of 2.  We have reported previously that, in unchlorinated compounds, the chain 
length connecting a phenyl group to the piperidine N is critical with respect to engendering a nH 
of 2 12.  Thus, in the series of N-substituted analogs (N-[CH2]nPh; n=1-6) with either the original 
ester (M29, M8, M6, M9, M10, M11 in order of ascending chain length) or an alcohol (M66, 
M5, M2, M4) at position Y, a maximum nH of ~2 is obtained when a propyl group connects the 
aromatic substituent to the N (M6 and M2). 
 
DA UPTAKE 
 
With the exception of 10, potency of these compounds against DA uptake generally parallels 
that against WIN binding, exhibiting discrimination ratio (DR; ratio of IC50 for DA uptake to IC50 
for WIN binding) values of between 1.8 and 3.4 (Table 3).  This consistent difference in affinity 
is most likely attributable to differences in assay conditions (e.g., WIN binding is determined at 
Cpd No. X Y Z WIN nH 
a
   
TMP H CO2CH3 H 0.92 ± 0.07 
M52
 
3,4-Cl CO2CH3 H 2.07 ± 0.05 
M29 H CO2CH3 Bn 1.08 ± 0.02 
M69 3,4-Cl CO2CH3 Bn 2.06 ± 0.20 
     
M62 3,4-Cl CH2OCH3 H 1.30 ± 0.13 
2 3,4-Cl CH2OCH3 CH3 1.16 ± 0.04 
M67 H CH2OCH3 Bn 1.12 ± 0.13 
M71 3,4-Cl CH2OCH3 Bn 2.23 ± 0.32 
 
M30 H OH H 1.07 ± 0.08 
M61 3,4-Cl OH H 1.08 ± 0.05 
11 H OH CH3 1.21 ± 0.16 
5 3,4-Cl OH CH3 1.01 ± 0.00 
M66 H OH Bn 1.08 ± 0.06 
M70 3,4-Cl OH Bn 1.88 ± 0.28 
 
10 3,4-Cl =CH2 CH3 1.15 ± 0.05 
 
M72 3,4-Cl CONH2 H 0.99 ± 0.11 
Y
N
Z
X
  
0o C and equilibrium, while DA uptake is measured at 37o C under non-equilibrium conditions).  
As with WIN binding, 1 was most potent in blocking DA uptake, while 11 was least potent. The 
one outlier in this group was 10, which had a DR of 5.2.  Although the reason for this is not 
clear, it is interesting to note that this is the only compound in this series with a planar 
configuration at the Y position, thus resulting in both restricted rotation and a very different 
conformational profile than the other threo compounds.  
 
CIT BINDING 
 
In general, these compounds had low affinity for the CIT binding site on the  5HT transporter, 
with IC50‘s ranging from 380 nM to >>10,000 nM. Table 3 shows the selectivity (ratio IC50 
against CIT/ IC50 against WIN) for all compounds for which CIT binding was determined. 
Whereas TMP has very high selectivity for WIN (>>120), COC is fairly nonselective (i.e., it is 
only 2.5-fold more potent at the WIN binding site than at the CIT binding site). Only one TMP 
analog, 10, was truly nonselective (0.6) and was actually slightly more potent against CIT 
binding than WIN binding. The low affinity compound 11 likely had low selectivity (>1.4), but a 
precise determination could not be made. Where comparisons could be made, the remaining 
compounds manifested moderate to great selectivity for the WIN binding site over the CIT 
binding site, ranging from 6 to >250. 
 
 Some trends were evident. When the ester of TMP was replaced with a substituted double 
bond as in 3 and 4, high selectivity was maintained (>250 and 155, respectively). When the 
double bond of these compounds was reduced yielding 8 and 9, the selectivity was lowered 
(>60 and 16, respectively). The unsubstituted double bond of 7 also retained high selectivity 
(>92). 
Table 3. Relative Affinity, Selectivity and Discrimination Ratio (DR) 
for TMP Analogs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Com- 
pound 
No. 
WIN Selectivity 
 
DR
 
IC50 
(nM) 
Relative affinity 
compared to 
TMP 
IC50  against CIT 
IC50  against WIN 
IC50  against DA 
IC50  against WIN 
COC 
 
160  
 
0.53 
2.5 2.5 
TMP 84.3 1.0 >>120 2.7 
1 27.0 3.1 ND 2.0 
2 28.0 3.0 17 2.4 
3 40.0 2.1 >250 3.0 
4 40.2 2.1 155 2.0 
5 64.2 1.3 6.0 3.4 
6 106 0.80 35 2.1 
7 109 0.77 >92 2.2 
8 168 0.50 >60 2.2 
9 193 0.44 16 1.8 
10 645 0.13 0.6 5.2 
11 7,030 0.012 >1.4 1.8 
  
While quite potent at the WIN binding site, 2 had relatively lower selectivity (17). Comparing 
this to 5, which only differs from 2 in being an alcohol rather than a methyl ether, revealed 
considerably lower selectivity (6). Finally compared to TMP, the ethyl ether analog 6 is much 
less selective (>120 and 35, respectively). 
 
The four compounds with N-methyl groups, 2, 5, 10, and 11, all had much lower selectivity 
than TMP (17, 6, 0.6, >1.4 and >>120, respectively). 
 
The increase in affinity for the WIN binding site described above that was observed in the 3,4-
dichloro analogs of TMP derivatives was also observed for CIT binding. In this instance, 5 was 
>26-fold more potent than 11 at the CIT binding site. 
 
CHEMISTRY 
 
Most of the reactions used in this work were routine and the results are as expected. The one 
exception was the elimination of the hydroxyl group of M61 under basic conditions to give 10. 
A possible mechanism for this reaction involves attack of the alkoxide on the solvent to form 
the intermediate 13 as shown in Fig 1, which would have an enhanced leaving group.  
 
Figure 1. Possible mechanism for elimination of hydroxyl group under basic conditions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
PHARMACOLOGICAL TESTING OF EXPERIMENTAL COMPOUNDS 
WIN and CIT binding and DA uptake were determined in rat brain preparations, as described 
previously 1, 5 . 
 
SYNTHESIS OF EXPERIMENTAL COMPOUNDS 
All of the compounds were synthesized using standard methods of organic chemistry. All were 
fully characterized including: quantitative elemental, 1H-NMR, 13C-NMR, MS, IR analyses and 
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in some cases X-ray. For reasons beyond the authors’ control, the 1H-NMR, 13C-NMR, MS, IR 
and X-ray data were lost before this publication was complete. These data fully confirmed the 
purity, structure and the stereochemistry (threo and trans double bond in some cases) of all of 
the compounds, but cannot be presented. The syntheses of compounds 1 - 11 are 
summarized in Schemes 1-4 and full experimental details and quantitative elemental data are 
presented for all compounds in the following Experimental Procedures section.  
 
EXPERIMENTAL PROCEDURES 
 
General Methods. Starting materials and solvents were purchased from either Aldrich 
Chemical Co. or Fisher Scientific and used without further purification. Flash chromatography 
was run using 230-400 mesh silica gel. Melting points were determined on a Mel-Temp 
apparatus and are uncorrected. 1H and 13C spectra were obtained on a Varian Gemini-300 
Spectrometer. High-resolution mass spectra [EI (electron ionization), CI (chemical ionization) 
or FAB (fast atom bombment)] were recorded on a VG Analytical 70-SE mass spectrometer 
equipped with a 11-250J data system. Elemental analyses were obtained from Atlantic 
Microlabs, Atlanta, GA. Free bases were dissolved in EtOAc or MeOH and converted to HCl 
salts by the addition of 1M HCl (1.5 equiv.) in diethylether. The excess HCl was removed 
under reduced pressure and the solid was recrystallized from various mixtures of MeOH and 
EtOAc. Nomenclature of compounds: TMP is methyl 2-phenyl-2-(piperidin-2-yl)acetate, ritalinic 
acid is 2-phenyl-2-(piperidin-2-yl)acetic acid and ritalinol is 2-phenyl-2-(piperidin-2-yl)ethanol. 
All structures are shown in Table 1 and Schemes 1-4. 
 
Scheme 1 Experimental 
()-threo-N-(benzyl)ritalinol ethyl ether (1).  
A mixture of 248 mg of ground KOH and 5 mL of DMSO was stirred at 55 oC for 20 min under 
an N2 atmosphere. The alcohol M66 (250 mg, 0.84 mmol) in 5 mL of DMSO was added 
followed by 110 uL (1.47 umol) of EtBr. Stirring was continued overnight, 80 mL of CH2Cl2 was 
added, the mixture was washed 5x20 mL of water and the organic layer dried with MgSO4. 
Evaporation of the solvent gave 284 mg of yellow liquid. Silica gel chromatography using 1% 
EtOAc in hexane gave 159 mg (58%) of pure 1. A sample, (45.6 mg), was converted to the 
HCl salt, 52 mg, mp 238-240 oC. Anal: Calc for C22H30ClNO; C 73.41, H 8.40, N 3.89, Cl 9.85. 
Found; C 73.55, H 8.60 N 3.81 Cl 9.70. 
 
()-threo-ritalinol ethyl ether (6).  
A mixture of 88.5 mg of 1, 10 mL of MeOH and 25 mg of Pd(OH)2 (20%, wet) was stirred under 
a H2 atmosphere (65 psi) for 2.5 h. Filtration and evaporation of the solvent gave 58.1 mg 
(94%) of pure 6. The HCl salt was too hydroscopic to purify. Anal: Calc for free base 
C15H23NO; C 77.21, H 9.93, N 6.60. Found; C 76.97, H 9.98 N 6.29. 
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Scheme 2 Experimental 
()-threo-(E)-methyl 4-phenyl-4-(piperidin-2-yl)but-2-enoate (3).  
A mixture of 1.46 g TMP (5.40 mmol), 40 mL of CHCl3, 20 mL H2O, 0.84 g NaHCO3, 1.0 g 
NaCl and 1.39g (BOC)2O was heated under reflux for 2 h. An additional 30 mL of CHCl3 was 
added and the organic layer washed with 1N HCl (2x25 mL) and then water. Drying and 
evaporation gave 2.01 g of pure product with a small excess of (BOC)2O. This product was 
dissolved in 30 mL of Et2O, cooled to 0 
oC and 6.6 mL of 1.0M LiAlH4 added. After stirring for 1 
h, the temperature was allowed to rise to RT over 1 h, water was carefully added followed by 
100 mL of Et2O. The organic layer was washed with water, dried and evaporated. This gave 
1.60 g (97%) of the N-BOC protected alcohol as a pure, white solid, mp 101-102 oC. A portion 
(419 mg), dissolved in 6 mL of CH2Cl2, was added to a suspension of PCC (443 mg) in 12 mL 
of CH2Cl2 and stirred for 2 h at RT. Filtration and evaporation gave 365 mg of nearly pure 
aldehyde 12. This material was dissolved in 12 mL of CH2Cl2 and 1.2 eq of (Ph)3P=CHCO2CH3 
added and then stirred at RT for 36 h. After evaporation, the oil was dissolved in 5% 
EtOAc/hexane and cooled to remove some of the (Ph)3P=O. The soluble material was 
chromatographed on silica using 20% EtOAc/hexane to give 480 mg (65 %) of N-BOC ester. 
This material was mixed with 6 mL of TFA, stirred for 40 min, evaporated and treated with 
EtOAc and NaCO3 to give after drying and evaporation, 325 mg (94%) of pure 3. This material 
  
was converted to the HCl salt, which gave perfect crystals from EtOAc/MeOH, mp 243-244 oC. 
Both 1H-NMR and single crystal Xray analysis showed the it was the trans (E) isomer. Anal: 
Calc for C16H22ClNO2; C 64.97, H 7.50, N 4.74, Cl 11.99. Found; C 65.11, H 7.59 N 4.74 Cl 
12.06. 
 
()-threo-(E)-2-1,3-diphenylallyl)piperidine (4). 
To a mixture of 275 mg of (Ph)3P
+-CH2Ph Br
- and NaH (0.55 mmol) in 5 mL of CH2Cl2 was 
added 138 mg (0.46 mmol) of 12. After stirring 5 days, 30 mL of EtOAc was added, washed 
with water, dried and evaporated to give N-BOC product. Chromatography with 2 % EtOAc in 
hexane yielded 134 mg (85%) of pure product. Treatment with TFA as described above, gave 
98 mg (100%) of 4. The HCl salt was crystallized from EtOAc/MeOH to give pure 4, mp 279-
281 oC. 1H-NMR analysis showed that it was the trans (E) isomer. Anal: Calc for C20H24ClN; C 
76.54, H 7.71, N 4.46, Cl 11.30. Found; C 76.42, H 7.71, N 4.44, Cl 11.42.   
 
()-threo-2-(1-phenylallyl)piperidine (7). 
NaH (132 mg) in 1.6 mL of DMSO was heated to 75 oC for 40 min, cooled to RT and 1.18 g 
(2.33 mmol) of (Ph)3P
+-CH2 Br
- in 4 mL of DMSO added. After 10 min, 200 mg of 12 was 
added and after stirring overnight, 20 mL of water was added and extracted with 5x40mL of 
hexane. Drying and evaporation gave the N-BOC product. Chromatography with 2 % EtOAc in 
hexane yielded 155 mg (78%). Treatment with TFA as described above, gave 88 mg (88 %) of 
7. The HCl salt was crystallized from EtOAc/MeOH to give pure 7, mp 180-182 oC. Anal: Calc 
for C14H20ClN; C 70.72, H 8.48, N 5.89, Cl 14.01. Found; C 70.86, H 8.58, N 5.84, Cl 14.83. 
 
()-threo-2-(1,3-diphenylpropyl)piperidine (9). 
A mixture of 100 mg of 4, 10 mL of MeOH and 25 mg of Pd (5% on C) was stirred under a H2 
atmosphere (45 psi) for 2 h. Filtration and evaporation of the solvent gave 78 mg of pure 9. 
The HCl salt was prepared. Anal: Calc for C20H26NCl; C 76.05, H 8.30, N 4.45, Cl 11.22. 
Found; C 76.40, H 8.32, N 4.31, Cl 11.04. 
 
()-threo-methyl 4-phenyl-4-(piperidin-2-yl)butanoate (8). 
Using the same procedure as in the preparation of 9, 155 mg of 3 gave 141 mg of pure 8. The 
HCl salt showed mp 192-193 oC. Anal: Calc for C16H24NO2Cl; C 64.53, H 8.12, N 4.70, Cl 
11.90. Found; C 64.42, H 8.22, N 4.69, Cl 12.01. 
 
Scheme 3 Experimental 
()-threo-N-(methyl)ritalinol (11).  
A mixture of 413 mg M30, 570 mg of K2CO3,14 uL of MeI (1.1 eq) and 10 mL of DMF was 
stirred at RT for 22 h under a N2 atmosphere. (Et)2O (70 mL) was added, the mixture was 
washed 5x25 mL of water and the organic layer dried with MgSO4. Evaporation of the solvent 
followed by silica gel chromatography using 1% EtOAc in hexane gave 246 mg of a pure oil. A 
solid HCl salt could not be prepared. Anal: Calc for C14H21NO; C 76.67, H 9.65, N 6.39. Found; 
C 76.39, H 9.86 N 6.19. 
 
()-threo-3,4-dichloro-N-(methyl)ritalinol (5). 
Using the same procedure as in the preparation of 11, 123 mg of M61 gave 141 mg of solid 5, 
which was recrystallized from EtOAc/hexane (4/96) and showed mp 101-102.6 oC. Anal: Calc 
for C14H19Cl2NO; C 58.34, H 6.64, N 4.86, Cl 24.60. Found; C 58.55, H 6.70 N 4.82, Cl 24.78. 
 
  
Scheme 4 Experimental 
()-threo-3,4-dichloro-N-(methyl)ritalinol methyl ether (2). 
Using the same procedure as in the preparation of 11, 121 mg of M62 gave 83 mg of pure 2, 
as an oil. The HCl salt was too hydroscopic to isolate. Anal: Calc for C15H21Cl2NO; C 59.61, H 
7.00, N 4.86, Cl 23.46. Found; C 59.83, H 7.09, N 4.51, Cl 23.10. 
 
2-(1-(3,4-dichlorophenyl)vinyl)-1-methylpiperidine (10) 
A mixture of 125 mg of ground KOH and 15 mL of DMSO was stirred at RT for 20 min under a 
N2 atmosphere. The alcohol M61 (126 mg, 0.46 mmol) in 5 mL of DMSO was added followed 
by 87 uL (3 eq) of MeI. Stirring was continued overnight, 60 mL of CH2Cl2 was added, the 
mixture was washed 5x20 mL of water and the organic layer dried with MgSO4. Evaporation of 
the solvent gave 125 mg of yellow liquid, which was obviously a mixture by TLC. Silica gel 
chromatography using 1% EtOAc in hexane gave 28 mg of pure 10. Anal: Calc for 
C14H17Cl2N;C 62.23, H 6.34, N 5.18, Cl 26.24. Found; C 61.82, H 6.73, N 4.79 Cl 25.88. 
 
CONCLUSIONS   
 
All compounds in this study are modified at the ester function on the TMP molecule. Other 
modifications include dichlorination of the phenyl ring and/or substitution of the piperidinyl 
nitrogen. These changes have significant effects on its activity against WIN and CIT binding, 
as well as synaptosomal DA transport. 
 
The synthesis and testing of the compounds reported here suggest several avenues for further 
exploration. Compounds 1 through 4 are of interest because they are significantly more potent 
than TMP itself. Of these four compounds, 3 merits special attention because of its very high 
selectivity for the WIN over the CIT binding site. Thus, its pharmacological profile should more 
closely resemble that of TMP rather than COC. In comparison, 5 is slightly more active than 
TMP, but much less selective, and might be somewhat more COC like.   
 
Even though less potent than TMP, 10 has several features that recommend it for further 
study. Its rigid planar conformation at position Y (what was an asymmetric carbon of the parent 
compound) could make it a useful tool for elucidating the structural details of the stimulant 
binding site. This compound also exhibits the highest DR of this series. If this finding reflects 
an actual difference in the activity of this compound against DA uptake relative to WIN binding, 
it may prove effective in blocking COC binding at doses that have a lesser effect on DA 
uptake, making it useful as a treatment for COC addiction. Moreover, it is the only compound 
of this series with no selectivity for the WIN over the CIT binding site: the modifications 
incorporated into the molecule caused it to lose potency for the WIN binding site while it gained 
potency at the CIT binding site, compared to TMP. This characteristic could make it a useful 
tool for the comparison of the neurotransmitter uptake sites on the DA and 5HT transporters. 
 
The three dichlorinated compounds reported here (2, 5, and 10), combined with halogenated 
and other TMP derivatives previously described by us 1, 5, 7, 12  should yield useful clues as to 
the positive cooperativity that can be induced at the WIN binding site. This is a relatively 
unexplored area, but one that holds great promise for advancing our understanding of the DA 
transporter. 
 
  
APPENDIX 
Table A.  WIN Binding for Selected Methylphenidate Analogs 
 
 
 
Com-
pound a 
X b Z b Y b IC50 (nM)
 c nH 
c,d 
M1 -H -CH2 N C S
 
-CO2CH3 422 ± 13 1.46 ± 0.06 
M2 -H -(CH2)3Ph -CH2OH 194 ± 14 1.92 ± 0.01 
M3 -H -CH2C≡CH -CO2CH3 821 ± 100 1.10 ± 0.20 
M4 -H -(CH2)4Ph -CH2OH 623 ± 64 1.54 ± 0.08 
M5 -H -(CH2)2Ph -CH2OH 1430 ± 150 1.09 ± 0.02 
M6 -H -(CH2)3Ph -CO2CH3 267 ± 13 1.78 ± 0.05 
M7 -H 
-CH2
Cl
 
-CO2CH3 106 ± 24 1.36 ± 0.16 
M8 -H -(CH2)2Ph -CO2CH3 678 ± 46 1.21 ± 0.02 
M9 -H -(CH2)4Ph -CO2CH3 205 ± 44 1.34 ± 0.18 
M10 -H -(CH2)5Ph -CO2CH3 1570 ± 80 1.27 ± 0.07 
M11 -H -(CH2)6Ph -CO2CH3 656 ± 17 0.95 ± 0.05 
M12 -H 
-CH2
Cl
 
-CO2CH3 243 ± 40 1.19 ± 0.09 
M13 -H -CH2CH=CH2 -CO2CH3 597 ± 4 0.97 ± 0.04 
M14 -H -CH2 Cl
 
-CO2CH3 31.2 ± 5.7 1.45 ± 0.12 
M15 -H -CH2 NO2
 
-CO2CH3 113 ± 3 1.02 ± 0.07 
M16 -H -CH2 OCH3
 
-CO2CH3 79.1 ± 1.4 1.21 ± 0.03 
M17 -H 
S
-CH2 Cl
 
-CO2CH3 392 ± 15 2.31 ± 0.26 
M18 -H 
N
-CH2
 
-CO2CH3 369 ± 4 1.10 ± 0.08 
M19 -H 
N
-CH2
 
-CO2CH3 173 ± 15 1.07 ± 0.04 
Y
N
Z
X
  
M20 -H N-CH2
 
-CO2CH3 128 ± 13 1.16 ± 0.01 
M21 -H 
O
-CH2
 
-CO2CH3 536 ± 38 1.06 ± 0.10 
M22 -H S
-CH2
 
-CO2CH3 143 ± 25 1.01 ± 0.00 
M23 -H 
S
-CH2
 
-CO2CH3 224 ± 1 1.25 ± 0.05 
M24 -H O
-CH2
 
-CO2CH3 459 ± 67 1.08 ± 0.01 
M25 -H -CH2CH3 -CH2OH 2340 ± 780 0.85 ± 0.06 
M26 3’,5’-diCH3 -H -CO2CH3 4690 ± 60 0.96 ± 0.05 
M27 3’,5’-diCl -H -CO2CH3 65.6 ± 5.4 1.16 ± 0.01 
M28 -H 
-CH2
Cl
 
-CH2OH 25.8 ± 0.2 1.21 ± 0.04 
M29 f -H -CH2Ph -CO2CH3 52.9 ± 2.3 1.08 ± 0.02 
M30 -H -H -CH2OH 448 ± 8 1.07 ± 0.08 
M31 g 4’-OH -H -CO2CH3 98.0 ± 10 1.07 ± 0.12 
M32 
3’-CH2OH, 
4’-OCH2OH 
-CH3 -CO2CH3 620 ± 40 1.04 ± 0.02 
M33 4’-OH -CH3 -CO2CH3 1220 ± 140 1.05 ± 0.01 
M34 g 4’-NO2 -H -CO2CH3 494 ± 33 1.18 ± 0.10 
M35 g 3’-NH2 -H -CO2CH3 265 ± 5 1.06 ± 0.13 
M36 g 4’-NH2 -H -CO2CH3 34.5 ± 4.0 0.96 ± 0.09 
M37 g 4’-OCH3 -H -CO2CH3 83.0 ± 11 0.83 ± 0.10 
M38 g 4’-Cl -H -CO2CH3 20.6 ± 3.4 1.17 ± 0.09 
M39 g -H -H -CO2CH3 83.0 ± 7.9 0.90 ± 0.09 
M40 g 4’-t-butyl -H -CO2CH3 13500 ± 450 1.12 ± 0.08 
M41 h 3’-Cl -CH3 -CO2CH3 160 ± 18 0.96 ± 0.04 
M42 e 4’-I -H -CO2CH3 14.0 ± 0.0 1.10 ± 0.04 
M43 e 3’-Br -H -CO2CH3 4.18 ± 0.17 1.14 ± 0.07 
M44 f 4’-CH3 -CH3 -CO2CH3 140 ± 9 1.02 ± 0.03 
M45 e 2’-Br -H -CO2CH3 1870 ± 135 0.93 ± 0.00 
M46 g 2’-OCH3 -H -CO2CH3 101000 ± 10000 0.94 ± 0.09 
M47 g 3’-OCH3 -H -CO2CH3 288 ± 52 1.11 ± 0.16 
M48 g 2’-OH -H -CO2CH3 23100 ± 50 1.04 ± 0.04 
M49 g 3’-OH -H -CO2CH3 321 ± 1 1.09 ± 0.02 
M50 g 3’-Cl -H -CO2CH3 5.1 ± 1.6 0.95 ± 0.02 
M51 g 4’-F -H -CO2CH3 35.0 ± 3.0 0.97 ± 0.02 
M52 g 3’,4’-diCl -H -CO2CH3 5.30 ± 0.70 2.07 ± 0.05 
M53 g 3’,4’-diOCH3 -H -CO2CH3 810 ± 10 1.12 ± 0.00 
M54 e 4’-Br -H -CO2CH3 6.90 ± 0.10 1.15 ± 0.07 
M55 g 2’-Cl -H -CO2CH3 1950 ± 230 0.98 ± 0.02 
M56 g 2’-F -H -CO2CH3 1420 ± 120 0.90 ± 0.02 
M57 g 3’-F -H -CO2CH3 40.5 ± 4.5 0.85 ± 0.10 
M58 g 4’-CH3 -H -CO2CH3 33.0 ± 1.2 1.05 ± 0.02 
  
M59 g 3’-CH3 -H -CO2CH3 21.4 ± 1.1 1.01 ± 0.12 
M60 3’-F -H -CH2OH 281 ± 32 1.08 ± 0.05 
M61 3’,4’-diCl -H -CH2OH 4.20 ± 0.52 1.08 ± 0.05 
M62 3’,4’-diCl -H -CH2OCH3 1.70 ± 0.24 1.30 ± 0.13 
M63 3’-Cl -CH2Ph -CO2CH3 41.2 ± 3.4 1.93 ± 0.20 
M64 -H -CH2Ph -CON(CH3)2 1730 ± 52 1.01 ± 0.03 
M65 -H -CH2Ph -CONH2 384 ± 8 1.00 ± 0.02 
M66 h -H -CH2Ph -CH2OH 23.7 ± 3.3 1.08 ± 0.06 
M67 h -H -CH2Ph -CH2OCH3 17.8 ± 1.1 1.12 ± 0.13 
M68 -H -H -CH2OCH3 97.1 ± 10.3 0.97 ± 0.04 
M69 3’,4’-diCl -CH2Ph -CO2CH3 76.3 ± 2.7 2.06 ± 0.20 
M70 3’,4’-diCl -CH2Ph -CH2OH 2.74 ± 0.35 1.88 ± 0.28 
M71 3’,4’-diCl -CH2Ph -CH2OCH3 4.2 ± 1.2 2.23 ± 0.32 
M72 3’,4’-diCl -H -CONH2 16.4 ± 2.4 0.99 ± 0.11 
M73 -H -H -CO2CH2Ph 1020 ± 130 1.04 ± 0.11 
M74 3’-CH3 -CH3 -CO2CH3 108 ± 16 1.00 ± 0.04 
M75 -H -H -CH2O(CO)CH3 690 ± 270 0.91 ± 0.04 
M76 -H -H -CONH2 1730 ± 170 0.91 ± 0.04 
M77 h -H -CH3 -CO2CH3 499 ± 25 1.00 ± 0.01 
M78 4’-C2H5 -H -CO2CH3 737 ± 78 0.96 ± 0.03 
M79 i 3’,4’-benzo -H -CO2CH3 11.0 ± 2.5 1.01 ± 0.03 
M80 i 4’-CF3 -H -CO2CH3 615 ± 15 0.97 ± 0.05 
a Unless otherwise referenced in the first column, the syntheses of the compounds and WIN 
binding data shown here were reported previously in Misra et al. 7.  M39 is the parent 
compound, (±)-threo-methylphenidate (TMP).   
b Naming convention for X substituents is based on the six positions of the phenyl ring: e.g. 
M48 (2’-OH TMP) has the -OH substituent at the 2’-position of the phenyl ring. “Benzo” refers 
to a 1,2-disubstituted benzene ring (3’,4’-benzo=alpha naphthyl analogue). For Y and Z 
substituents, Ph = phenyl. 
c Binding and nH data were generated in the laboratory of MMS.  Values are expressed as the 
mean ± standard error of the mean (SEM) of 2-7 assays for each compound. 
d Hill coefficient of [3H]WIN 35,428 binding.  Unless otherwise referenced in Column 1, these 
values represent previously unpublished data. 
e Compounds M42, M43, M45, and M54 were provided by Dr. S. J. Gatley of Brookhaven 
National Laboratories. 
f Synthesis and binding studies have been described elsewhere. 10 
g Synthesis and binding studies have been described elsewhere. 1 
h Synthesis and binding studies have been described elsewhere. 5 
i Synthesis and binding studies have been described elsewhere. 4 
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